Xenon Pharmaceuticals Inc (XENE)
EBITDA Growth
-18.34%
Quarterly · Period ending:
XENE EBITDA Growth
Year-over-year change vs the same period a year earlier
Latest reported-18.34%period ending
Latest reported-18.34%period ending
XENE Quarterly EBITDA YoY % (566.99% → -18.34%)
Year-over-year change
High-resolution chart · PNG
XENE ebitda growth history
Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | EBITDA Growth |
|---|---|
| -18.3403% | |
| -55.0257% | |
| -35.4849% | |
| -22.7499% | |
| -36.7118% | |
| -23.3068% | |
| -45.4167% | |
| -35.266% | |
| -24.4284% | |
| -20.0382% | |
| -35.748% | |
| -42.8382% | |
| -83.7742% | |
| -186.5709% | |
| -58.45% | |
| -145.4351% | |
| -34.4591% | |
| -7.1235% | |
| -93.1295% | |
| -73.163% | |
| -20,910.2804% | |
| -124.9752% | |
| -16.514% | |
| -5.8102% | |
| 101.118% | |
| 35.1155% | |
| -35.4591% | |
| 38.0696% | |
| -28.487% | |
| -215.3511% | |
| -1.9737% | |
| -79.0599% | |
| 3.5603% | |
| 55.9448% | |
| -49.2447% | |
| -5.7231% | |
| -26.271% | |
| -45.4985% | |
| -128.3743% | |
| -1,183.871% | |
| -1,363.843% | |
| 9.3423% | |
| -1,066.25% | |
| -106.3094% | |
| -68.8345% | |
| -591.3007% | |
| -89.0561% | |
| 32.4349% | |
| 100.9056% | |
| 56.1449% | |
| 253.3566% | |
| 566.993% |